Emerging technology has a brilliant future: the CRISPR-Cas system for senescence, inflammation, and cartilage repair in osteoarthritis

• Published in: Cellular & molecular biology letters Vol. 29; no. 1; pp. 64 - 30
• Main Authors: Jia, Shicheng, Liang, Rongji, Chen, Jiayou, Liao, Shuai, Lin, Jianjing, Li, Wei
• Format: Journal Article
• Language: English
• Published: England BioMed Central 02.05.2024; BMC
• Subjects: Animals; Arthritis; Cartilage; Cartilage - metabolism; Cartilage - pathology; Cartilage diseases; Cartilage repair; Cartilage, Articular - metabolism; Cartilage, Articular - pathology; Cellular senescence; Cellular Senescence - genetics; Chronic pain; CRISPR; CRISPR-Cas system; CRISPR-Cas Systems - genetics; Cytokines; Enzymes; Gene Editing - methods; Gene therapy; Genetic Therapy - methods; Genome editing; Genomes; Genomics; Humans; Inflammation; Inflammation - genetics; Molecular biology; Musculoskeletal system; Osteoarthritis; Osteoarthritis - genetics; Osteoarthritis - therapy; Senescence; Signal transduction; Trauma; CRISPR-Cas system; Inflammation; Cartilage repair; Osteoarthritis; Cellular senescence
• ISSN: 1689-1392; 1425-8153; 1689-1392
• DOI: 10.1186/s11658-024-00581-x

Osteoarthritis (OA), known as one of the most common types of aseptic inflammation of the musculoskeletal system, is characterized by chronic pain and whole-joint lesions. With cellular and molecular changes including senescence, inflammatory alterations, and subsequent cartilage defects, OA eventually leads to a series of adverse outcomes such as pain and disability. CRISPR-Cas-related technology has been proposed and explored as a gene therapy, offering potential gene-editing tools that are in the spotlight. Considering the genetic and multigene regulatory mechanisms of OA, we systematically review current studies on CRISPR-Cas technology for improving OA in terms of senescence, inflammation, and cartilage damage and summarize various strategies for delivering CRISPR products, hoping to provide a new perspective for the treatment of OA by taking advantage of CRISPR technology.